What is CNTB's market cap?

$49.15M, based on the Nov 4 close of $0.78.

Does Connect Biopharma Holdings Limited pay a dividend?

No regular cash dividend has been paid in the last year.

How much of CNTB is sold short?

3.9M shares, 18.7% of float, as of Oct 15, 2026.

What sector is CNTB in?

Healthcare, in the Pharmaceuticals industry.

NASDAQ · CNTBHealthcarePharmaceuticals

Connect Biopharma Holdings Limited Ordinary Shares (CNTB)

$0.7805+0.83%

Close Nov 4, 2026 · split-adjusted

Nov 4, 2026$0.78▼ 53.54% in range

Nov 4, 2025Low $0.76 · High $3.69Nov 4, 2026

What changed · written from our data

As of Nov 4, 2026

Connect Biopharma Holdings Limited closed at $0.78 on Nov 4, up 0.83%, within 2.4% of its 52-week closing low. Volume of 300.0K shares was 0.29× its 20-day average (below normal).

Split-adjusted performance: -13.8% over one month, -68.5% over six months, -52.7% over one year.

In the quarter ended Jun 30, 2026, revenue was $2.77M, up 5666.7% from a year earlier, with a net margin of -624.4%.

Short interest was 3.9M shares at the Oct 15 settlement, up 10.2% from the prior report (18.7% of float, 1.7 days to cover).

Market cap$49.2M63.0M shares

Revenue · quarter$2.8M+5666.7% YoY

Diluted EPS$-0.27—

P/E · TTM—P/S 16.6×

Net margin-624.4%Gross 100.0%

Dividend yieldNone

52-week range0.76 – 3.69−78.8% from high

Volume300.0K0.29× 20-day avg

Volatility · 60d137.4%Annualised

Short % of float18.7%1.7 days to cover

Net cash$31.5MCash $31.5M

Next earnings—Not scheduled

Split-adjusted performance

1W −7.7%1M −13.8%3M −64.4%6M −68.5%YTD −72.3%1Y −52.7%3Y −41.3%5Y −95.3%

Earnings reactions

History →

No reported quarters with price history yet.

Rank within Pharmaceuticals

Percentile among 420 companies (100 = best)

6-month momentum12

Revenue growth98

Net margin27

Value (low P/E)—

Size30

Industry medians: 6-month return −25.5%, revenue growth +6.2%, net margin −33.8%, P/E 16.1×.

Short interest

Details →

Shares short3.9M+10.2% vs prior

Days to cover1.7Settled Oct 15

% of float18.7%

Short vol. 10d52.5%of daily volume

Closest peers by size in Pharmaceuticals

Company	Price	Today	6M	Rev. growth	Net margin	P/E	Mkt cap
CNTBConnect Biopharma Holdings Limited	$0.7805	+0.83%	−68.5%	+5666.7%	−624.4%	—	$49.2M
GANXGain Therapeutics	$1.11	−3.48%	−41.9%	—	—	—	$48.4M	Compare
INMInMed Pharmaceuticals	$8.75	+420.83%	+1104.6%	—	—	—	$48.1M	Compare
IBIOiBio	$0.8000	−2.85%	−54.8%	−100.0%	—	—	$51.4M	Compare
ANVSAnnovis Bio	$1.21	+11.01%	−49.6%	—	—	—	$51.6M	Compare
HYPDHyperion DeFi	$3.07	+0.66%	−15.7%	—	4009.1%	—	$46.7M	Compare
PLRXPliant Therapeutics	$0.8518	−1.03%	−30.7%	—	—	—	$52.7M	Compare
HOWLWerewolf Therapeutics	$1.09	+1.87%	+67.6%	—	17.5%	—	$53.0M	Compare
OSTXOS Therapies Incorporated	$1.15	−0.86%	−33.5%	—	—	—	$53.8M	Compare

News about Connect Biopharma Holdings Limited

All news →

Here's Why Connect Biopharma Holdings (CNTB) Could be Great Choice for a Bottom FisherZacks Investment Research · Oct 19, 2026▲ Positive Connect Biopharma Reports First Quarter 2026 Financial Results and Provides Business UpdateGlobeNewswire Inc. · May 12, 2026▲ Positive

Quick answers

What does Connect Biopharma Holdings Limited do?: Connect Biopharma Holdings Ltd is a clinical-stage biopharmaceutical company dedicated to transforming care for asthma and chronic obstructive pulmonary disease (COPD). The company is advancing rademikibart, a next-generation antibody designed to target interleukin-4-receptor alpha.
What is CNTB's market cap?: $49.15M, based on the Nov 4 close of $0.78.
Does Connect Biopharma Holdings Limited pay a dividend?: No regular cash dividend has been paid in the last year.
How much of CNTB is sold short?: 3.9M shares, 18.7% of float, as of Oct 15, 2026.
What sector is CNTB in?: Healthcare, in the Pharmaceuticals industry.

About Connect Biopharma Holdings Limited

Connect Biopharma Holdings Ltd is a clinical-stage biopharmaceutical company dedicated to transforming care for asthma and chronic obstructive pulmonary disease (COPD). The company is advancing rademikibart, a next-generation antibody designed to target interleukin-4-receptor alpha. It is currently conducting clinical studies of rademikibart for the treatment of acute exacerbations of asthma and COPD. The company operates in one operating segment: treatment of respiratory diseases.

HQ: San Diego, CA64 employeesListed Sep 3, 2025connectbiopharm.com

Sources: Massive / Polygon daily aggregates (split-adjusted) · SEC filings via Massive · FINRA settlements via Massive · Financial Modeling Prep. Figures are dated where shown; research is informational, not investment advice. Methodology